Infanrix and Infanrix-hexa Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of routine immunization programs, rising awareness of pediatric infectious disease prevention, government-supported vaccination initiatives, availability of combination vaccine formulations, growth in public health infrastructure.

The growth in the forecast period can be attributed to increasing birth rates in emerging economies, expansion of universal immunization coverage, rising investments in vaccine manufacturing capacity, growing focus on combination vaccines to reduce dosage burden, increasing participation of global health organizations. Major trends in the forecast period include increasing adoption of combination pediatric vaccines, rising demand for hexavalent immunization programs, growing focus on cold chain optimization, expansion of national childhood vaccination schedules, enhanced emphasis on vaccine safety and compliance.

The increasing prevalence of pertussis cases is expected to propel the growth of the Infanrix and Infanrix-Hexa market going forward. Pertussis cases represent the number of reported instances of whooping cough, a highly contagious respiratory infection, over a defined period. The rise in pertussis cases is largely attributed to declining vaccination coverage, waning immunity over time, and a higher number of undiagnosed or misdiagnosed infections. The growing incidence of pertussis is increasing demand for Infanrix and Infanrix-Hexa vaccines, as they effectively protect against this highly contagious disease, supporting wider adoption and market expansion. For instance, in October 2024, according to the Health Protection Surveillance Centre, an Ireland-based agency specializing in communicable disease surveillance, approximately 514 pertussis cases were recorded in Ireland in 2024, a sharp rise compared to just 18 cases reported in 2023. Therefore, the rising prevalence of pertussis cases is driving the growth of the Infanrix and Infanrix-Hexa vaccine market.

The increase in child mortality is expected to drive the growth of the Infanrix and Infanrix-Hexa vaccine market going forward. Child mortality refers to the number of deaths among children under the age of 15 within a given timeframe. Higher child death rates are primarily caused by factors such as malnutrition, limited access to healthcare, infectious diseases, poor sanitation, and economic challenges. Infanrix and Infanrix-Hexa help reduce child mortality by offering protection against multiple serious and potentially fatal diseases through effective immunization. For instance, in March 2025, according to the United Nations International Children’s Emergency Fund, a US-based United Nations agency, approximately 4.8 million children under the age of five died globally in 2023, equivalent to about 13,100 deaths per day. Therefore, the rising number of child deaths is contributing to the growth of the Infanrix and Infanrix-Hexa vaccine market.

The rise in healthcare expenditure is expected to further support the growth of the Infanrix and Infanrix-Hexa market going forward. Healthcare expenditure refers to the total spending on healthcare services, including treatments, medications, and hospital care, over a specified period. Healthcare spending is increasing due to factors such as population aging, rising healthcare demands, advances in medical technology, and higher costs of services and pharmaceuticals. Increased healthcare expenditure facilitates the expansion of immunization programs and improves vaccine availability, supporting market growth. For instance, in May 2024, according to the Organisation for Economic Co-operation and Development, a France-based intergovernmental organization, average healthcare spending across OECD countries in 2024 was estimated at nearly USD 6,000 per capita after adjusting for purchasing power differences, with the United States being the highest spender. Therefore, the rise in healthcare expenditure is driving the growth of the Infanrix and Infanrix-Hexa market.

Major companies operating in the infanrix and infanrix-hexa market are GlaxoSmithKline plc.

North America was the largest region in the infanrix and infanrix-hexa market in 2025. The regions covered in the infanrix and infanrix-hexa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the infanrix and infanrix-hexa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the infanrix and infanrix-hexa market by increasing costs of imported vaccine raw materials, biological reagents, packaging components, and cold-chain logistics equipment required for large-scale immunization programs. Public health programs and hospital procurement systems in North America and Europe are most affected due to reliance on cross-border pharmaceutical supply chains, while emerging markets face higher vaccine procurement costs. These tariffs can delay vaccine distribution timelines and increase immunization program budgets. However, they are also encouraging regional vaccine manufacturing, localized fill-finish operations, and stronger domestic supply chain resilience for pediatric vaccines.

The infanrix and infanrix-hexa market research report is one of a series of new reports that provides infanrix and infanrix-hexa market statistics, including infanrix and infanrix-hexa industry global market size, regional shares, competitors with a infanrix and infanrix-hexa market share, detailed infanrix and infanrix-hexa market segments, market trends and opportunities, and any further data you may need to thrive in the infanrix and infanrix-hexa industry. This infanrix and infanrix-hexa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Infanrix and Infanrix-hexa are vaccines used to protect infants and young children from several serious infectious diseases. Infanrix is formulated to protect against diphtheria, tetanus, and pertussis (whooping cough) and is administered in multiple doses starting at 2 months of age to help prevent these infections. Infanrix-hexa, on the other hand, is a combination vaccine that provides protection against six diseases, including diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and *Haemophilus influenzae* type b (Hib).

The primary patient populations for Infanrix and Infanrix-hexa include infants, children, as well as adolescents and adults. Infants are defined as children under one year of age, and both vaccines are used to protect them from multiple infectious diseases. The clinical indications include diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis, and *Haemophilus influenzae* type b (Hib). These vaccines are distributed through hospitals, clinics, public health programs, and pharmacies and are used for primary immunization, booster doses, and in combination with other vaccines.

The infanrix and infanrix-hexa market consists of sales of Infanrix vaccines for diphtheria, tetanus, and whooping cough, Infanrix-hexa vaccines for diphtheria, tetanus, whooping cough, polio, hepatitis B, and Haemophilus influenzae type b and combination vaccines for infants and young children to protect against multiple infectious diseases. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.